By Daniella Parra Volcon (NASDAQ: VLCN) said it closed a $500 million private placement and will allocate over 95% of the proceeds to Bitcoin purchases. The company, which already holds 280.14 BTC, is rebranding as Empery Digital, Inc. with a...

By Daniella Parra ReAlta Life Sciences said Pegtarazimod is being evaluated in a Phase 2 trial across 13 U.S. NICUs for newborns with moderate to severe neuroinflammation in HIE. The company said that newborn rats treated with pegtarazimod after oxygen...

By Daniella Parra Vinson & Elkins has expanded its global aviation finance practice with the addition of Harry Upcott as a partner in its London office, it said. Upcott brings extensive experience advising on complex aviation and satellite financing, leasing,...

  By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug’s unique chemical structure, how it’s made,...

By Exec Edge Editorial Staff GameSquare Holdings (NASDAQ: GAME) said it completed a $70 million public offering, fueling a major expansion into decentralized finance with the launch of a $100 million Ethereum-based treasury strategy. The capital raise significantly exceeded earlier...

Download the Complete Report Here By Rayk Riechmann With 12 successful SPAC transactions representing over $7 billion in enterprise value as an advisor or sponsor, Daniel Hennessy’s Hennessy Capital Group (HCG) has one of Wall Street’s most impressive track records...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com

Download the Complete Report Here The wealth management world is undergoing a revolution. One likely victor for investors to consider is recently-listed Binah Capital Group, Inc. (Nasdaq: BCG), whose tech has what it takes to help financial advisors thrive in...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com

By Daniella Parra Inventiva said Dr. Jason Campagna has been named President of R&D and Chief Medical Officer as Inventiva advances lanifibranor, its lead candidate for MASH, with topline Phase 3 results from the NATiV3 trial expected in the second...